• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

In 2007, There Were 11 Highly Successful Targeted Cancer Blockbusters According To The New Report 'Oncology Pipelines: Is The Future Targeted Therapy?'

Posted on: Friday, 8 June 2007, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c59285) has announced the addition of new Decision Resources report Oncology Pipelines: Is the Future Targeted Therapy? to their offering.

Drug companies' cancer pipelines are bulging, and hundreds of new drugs are in development--the modern equivalent of a gold rush. Remarkable successes have been recorded with targeted oncology, but the treatment of more than 200 types of cancer remains a daunting task. Today's three principal modalities of cancer treatment--surgery, radiotherapy, drug treatment--have begun to give way to new targeted techniques.

Genentech/Roche/Chugai's Herceptin and ten other blockbuster "targeted" therapies have shown that drugs designed to interact with specific molecular targets can hit cancer where it hurts. However, targeted therapies are no panacea; to continue advancing cancer treatment, investigators must continue to improve their understanding of specific drug targets and continue to explore gene regulation and protein networks, to which targeted oncology therapies owe their existence.

Get the Answers You Need to Shape Your Strategy

- In 2007, there were 11 highly successful targeted cancer blockbusters. Which drugs were they, and which blockbusters also carried a strong warning label: namely, the dreaded "black box" authorized by the FDA?

- Amgen recently suffered several setbacks, including unfavourable trial results from a Phase III trial of Vectibix in first-line, metastatic colorectal cancer. But Amgen still has upward of 60 ongoing development programs. Why is this company still in need of a more vibrant pipeline?

- Bristol-Myers Squibb has a solid presence in targeted oncology drugs with its blockbuster drug Erbitux.

- Which other drug in Bristol-Myers Squibb's portfolio represents a significant achievement in the rational design of drugs to overcome drug resistance in cancer?

- With Avastin, Herceptin, and Rituxan/MabThera, Genentech and Roche are on track to rack up more than $11 billion in combined worldwide revenues in 2007. Competition is on the way, however. Which companies have drugs in Phase III trials for non-small-cell lung cancer? What are Genentech/Roche's strategies for expanding their prolific oncology franchise?

- For the last few years, ImClone has been sidetracked by legal issues; yet ImClone still claims a legitimate cancer blockbuster: Erbitux, the first targeted cancer therapy approved for colorectal cancer. Why have unfavorable results of Amgen's Vectibix made clinicians, investigators, and investors anxious about Erbitux's future potential?

- Much excitement accompanied the completion of sequencing the human genome, circa 2000. But the excitement soon gave rise to somber reflection: the sequencing itself did not immediately point the way to a bevy of new oncology drugs. What work still needs to be done for human genome sequencing to realize its promise of helping to provide personalized, targeted cancer therapies?

Scope

- Cancer therapy today and tomorrow: limitations of the three principal modalities of current cancer treatment; addressing unmet needs; targeted cancer therapy and personalized medicine; changes in the drug development paradigm.

- Leaders in oncology: the world's best-selling oncology drugs and the key products in 11 leading oncology franchises.

- Oncology pipelines: Amgen's woes; AstraZeneca's disappointment; Bristol-Myers Squibb's expansion; Exelixis's aggressive discoveries; Genentech/Roche's leading oncology franchise; Genmab's waves; GlaxoSmithKline's oncological advances; ImClone's legitimate blockbuster; ImmunoGen's "armed" technology; Novartis's kinase inhibitors; Pfizer's bandwagon-jumping.

- Waves of the future: human genome sequencing; the oncology gold rush; RNA targeted therapies.

- Spectrum expert commentaries: two separate commentaries in which leading oncology experts explore the challenges, discoveries, and intricate mechanisms of personalized cancer treatment and the use of microRNA modulators.

Content Outline:

Executive Summary

Strategic Considerations

Stakeholder Implications

Cancer Therapy Today and Tomorrow

Targeted Therapy--Hitting Cancer Where it Hurts

Leaders in Oncology

Today's Reality--Difficulties in Developing Targeted Therapies

Toxicities and Black Box Warnings

Personalized Medicine

Murphy's Law in Effect

Key Products in Development

AstraZeneca's Initial Disappointment Gives Rise to Changes

Bristol-Myers Squibb Expands into Biologics

Exelixis Engages in Aggressive Drug Discovery and Development

Third-Party Clinical Financing Vehicle

Small-Molecule Kinase Inhibitors

Genentech/Roche Lead the Way with Oncology Biologics

Genmab Makes Waves with Largest European Product Deal Ever

GlaxoSmithKline Advances into Herceptin's Space in Breast Cancer

ImClone Faces Ongoing Strife but Boasts a Legitimate Blockbuster

ImmunoGen Innovates with Armed Antibody Technology

Novartis Banks on Small-Molecule Kinase Inhibitors

Pfizer Moves beyond Historical Reliance on Small-Molecule Drug Technologies

Waves of the Future

Somber Reflection on Human Genome Sequencing

Mainstay Cancer Treatment Circa 2015

Personalized Targeted Therapies

Tomorrow's RNA Targeted Therapies

Spectrum Expert Commentaries:

"Targeted Oncology Therapy: Trend toward Personalized Treatment," by David Z. Chang, M.D., Ph.D., Gastrointestinal Medical Oncology & Immunology, The University of Texas, M.D. Anderson Cancer Center

"The Potential of MicroRNA Modulators as Targeted Oncology Therapies," by Fabricio F. Costa, Ph.D., Cancer Biology and Epigenomics Program, Children's Memorial Research Center, Northwestern University's Feinberg School of Medicine, and Thomas Wurdinger, Ph.D., Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School

List of Tables

List of Figures

Companies Mentioned:

- Abgenix

- Amgen

- AstraZeneca

- Bayer

- Biogen Idec

- Biotest

- Boehringer Ingelheim

- Bristol-Myers Squibb

- Cambridge Antibody Technology Group

- Centocor

- Chiron

- Chugai

- Eli Lilly

- Exelixis

- Genentech

- Genmab

- Genomic Health

- GlaxoSmithKline

- ImClone

- ImmunoGen

- Johnson & Johnson

- Medarex

- MedImmune

- Merck KGaA

- Merck Serono

- Millennium

- Novartis

- Onyx

- OSI Pharmaceuticals

- Pfizer

- Roche

- Sanofi -Aventis

- Schering

- Seattle Genetics

- UCB

- Wyeth

- Xoma

For more information visit http://www.researchandmarkets.com/reports/c59285

Source: Business Wire

More News in this Category